Nebenwirkungen · Rebif
Rebif 22 micrograms/0.5 mL solution for injection in cartridge · Abschnitt 4.8 · PDF-Seite 30
HOS-086765 · Präparat HOS-083347
The highest incidence of adverse reactions associated with Rebif therapy is related to flu-like syndrome. Flu-like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment. Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment. Approximately 30 % of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. Asymptomatic increases in laboratory parameters of hepatic function and decreases in white blood cells are also common.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T14:48:00Z · SHA-256 c6ab8814b49946dc4207aa21171665843c7aa81527cc4b3faf99df87529e0907 · Passage be0fc51ae54949ceaf9b88fc648ba9ea37633a164624e23ab405943432a62eb2 · Zeichen 31–681 im Abschnitt